Maintenance chemotherapy for ovarian cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD007414.pub2PMID 20824860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• Challenges for chemotherapy in ovarian cancer.

  2006cited by this paper
• A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma* A Ovary

  2005cited by this paper
• Treatment options in the management of ovarian cancer

  2005cited by this paper
• First-Line Therapy for Ovarian Carcinoma: What's Next?

  2004influential reference
• A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

  2004cited by this paper
• Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

  2004cited by this paper
• Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study

  2004cited by this paper
• Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.

  2003cited by this paper
• Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy

  2003cited by this paper
• Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.

  2003cited by this paper
• Ovarian cancer treatment: what is new

  2003cited by this paper
• First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.

  2003cited by this paper
• Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Globocan 2000 : cancer incidence, mortality and prevalence worldwide

  2001cited by this paper
• A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study.

  1997cited by this paper
• A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

  1993cited by this paper
• Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

  1992cited by this paper

• Identification of a novel chemotherapy benefit index for patients with advanced ovarian cancer based on Bayesian network analysis

  2025cites this paper
• Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

  2025influential citation
• CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies.

  2025cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2025 update

  2025cites this paper
• Tertiary cytoreduction for recurrence of ovarian CANCER patients after intraperitoneal chemotherapy

  2025cites this paper
• Correlation of maintenance chemotherapy and improved survival in patients with locally advanced unresectable pancreatic head adenocarcinoma receiving neoadjuvant chemotherapy and concurrent chemoradiotherapy.

  2024cites this paper
• Cutaneous Metastasis of Ovarian Tumor after Hysterectomy and Bilateral Salpingo-oophorectomy: A Case Report

  2024cites this paper
• Maintenance chemotherapy for esophageal squamous cell carcinoma after standard concurrent chemoradiotherapy: a national propensity score matching cohort study.

  2024cites this paper
• Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy

  2024cites this paper
• Identification of microRNA and protein interaction networks in human ovarian cancer

  2023cites this paper
• What are the effects of maintenance chemotherapy in women with ovarian cancer?

  2022cites this paper
• A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

  2022cites this paper
• Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis.

  2022cites this paper
• Impact of Environmentally Relevant Concentrations of Bisphenol A (BPA) on the Gene Expression Profile in an In Vitro Model of the Normal Human Ovary

  2022cites this paper
• Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

  2021cites this paper
• Current Ovarian Cancer Maintenance Strategies and Promising New Developments

  2021cites this paper
• NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis

  2020cites this paper
• Knockout of EGFL6 by CRISPR/Cas9 Mediated Inhibition of Tumor Angiogenesis in Ovarian Cancer

  2020cites this paper
• Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.

  2020cites this paper
• Carcinogenic effects of bisphenol A in breast and ovarian cancers.

  2020cites this paper
• Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".

  2019cites this paper
• Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer

  2019cites this paper
• [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

  2019cites this paper
• TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.

  2019cites this paper
• Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study

  2019influential citation
• Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis

  2019cites this paper
• Calcium homeostasis in cisplatin resistant epithelial ovarian cancer.

  2019influential citation
• Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis

  2019cites this paper
• Intraperitoneal Chemotherapy: Historic Anomaly or Hope for the Future?

  2018cites this paper
• An NF90/NF110-Mediated Feedback Amplification Loop Regulates DICER Expression and Controls Ovarian Carcinoma Progression

  2018cites this paper
• A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer

  2018cites this paper
• Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells

  2018cites this paper
• Piperine functions as a tumor suppressor for human ovarian tumor growth via activation of JNK/p38 MAPK-mediated intrinsic apoptotic pathway

  2018cites this paper
• Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review

  2018cites this paper
• Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

  2018cites this paper
• Diagnosis and Treatment of Ovarian Cancer.

  2018cites this paper
• Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

  2018cites this paper
• The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer

  2018cites this paper
• Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

  2018cites this paper
• Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

  2018cites this paper
• Real-time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin

  2018cites this paper
• Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer

  2017cites this paper
• Metastatic ovarian tumor of a lung cancer at the hospital center of Chauny (France): a case report

  2017cites this paper
• Interleukin-6/interleukin-6 receptor pathway as a new therapy target in ovarian cancer

  2017influential citation
• Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer

  2017cites this paper
• NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer

  2017cites this paper
• Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy

  2017cites this paper
• The expression of Duffy antigen receptor for chemokines by epithelial ovarian cancer decreases growth potential

  2017cites this paper
• OVARIAN CANCER

  2016cites this paper
• Phase II study of Vigil ® DNA engineered immunotherapy asmaintenance in advanced stage ovarian cancer

  2016cites this paper
• Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers

  2016cites this paper
• Differential Effects of Estradiol and Bisphenol A on SET8 and SIRT1 Expression in Ovarian Cancer Cells

  2016cites this paper
• Is there a current change of maintenance treatment in ovarian cancer? An updated review of the literature.

  2016cites this paper
• miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition

  2016cites this paper
• Anti-tumor effects of osthole on ovarian cancer cells in vitro.

  2016cites this paper
• Failure of Elevating Calcium Induces Oxidative Stress Tolerance and Imparts Cisplatin Resistance in Ovarian Cancer Cells

  2016cites this paper
• Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials

  2016cites this paper
• Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study

  2015cites this paper
• Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer

  2015cites this paper
• Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer.

  2015cites this paper
• Ovarian cancer treatment: The end of empiricism?

  2015cites this paper
• Expression of BAF57 in ovarian cancer cells and drug sensitivity

  2015cites this paper
• MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.

  2015cites this paper
• Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

  2014cites this paper
• Can we maximize both value and quality in gynecologic cancer care? A work in progress.

  2014cites this paper
• Maintenance therapy in ovarian cancer

  2014cites this paper
• Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch

  2014cites this paper
• Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin

  2014cites this paper
• Expression of Carbonic Anhydrases II, IX and XII in the Normal Female Reproductive Tract, Gynecological Tumors and Lynch Syndrome

  2014cites this paper
• Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents

  2014cites this paper
• Incorporation of pazopanib in maintenance therapy of ovarian cancer.

  2014cites this paper
• Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer.

  2014cites this paper
• Maintenance chemotherapy for ovarian cancer.

  2013cites this paper
• Maintenance Chemotherapy in Ovarian Cancer: A Trial-Sequential Analysis

  2013cites this paper
• Adverse Events Associated With Complementary and Alternative Medicine Use in Ovarian Cancer Patients

  2013cites this paper
• Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.

  2013cites this paper
• Microenvironment and Immunology Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M 2 Macrophages in the Tumor Microenvironment

  2013cites this paper
• Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

  2013cites this paper
• S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

  2013cites this paper
• Latest research and clinical treatment of advanced-stage epithelial ovarian cancer

  2013cites this paper
• Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.

  2013cites this paper
• Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review

  2013cites this paper
• Latest research and treatment of advanced-stage epithelial ovarian cancer

  2013cites this paper
• Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.

  2012cites this paper
• Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer.

  2012cites this paper
• Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.

  2012cites this paper
• Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.

  2011cites this paper
• Digital Commons @ University of South Florida Digital Commons @ University of South Florida

  year unknowncites this paper